Key result
VA-ECMO restores LVEF to 60% in infant with COVID-19 fulminant myocarditis.
Why the study?
Fulminant myocarditis in children during the COVID-19 pandemic was rare but carried high morbidity and mortality risk.
Case Report (n=1)
No
Prompt use of central VA-ECMO and CVVH can be an effective life-saving strategy for infants presenting with cardiogenic shock due to COVID-19-related fulminant myocarditis.
Supports VA-ECMO rescue in infant COVID-19 myocarditis; hypothesis-generating and requires prospective validation before practice change.
Fulminant myocarditis in children was rare during the coronavirus disease 2019 pandemic, but it had the potential for high morbidity and mortality. We describe the clinical course of a previously healthy 9-month-old young male infant who rapidly deteriorated into cardiogenic shock due to coronavirus disease 2019-related fulminant myocarditis. He developed severe heart failure and multiple organ dysfunction syndrome that were treated promptly with central venoarterial extracorporeal membrane oxygenation and continuous venovenous hemofiltration. He made a good recovery without significant morbidity.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2023) conducted a case report in Fulminant myocarditis with acute COVID-19 (n=1). VA-ECMO was evaluated on Clinical recovery and survival. VA-ECMO successfully supported a 9-month-old infant with COVID-19-related fulminant myocarditis and cardiogenic shock, leading to full recovery and an improvement in left ventricular ejection fraction from 19% to 60%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: